SHERPA™ Bioinformatics Engine

Systematic HLA Epitope Ranking Pan Algorithm

Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails the comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. The ImmunoID NeXT Platform® enables a comprehensive survey of putative neoantigens by combining highly sensitive exome scale DNA and RNA sequencing with advanced analytics. We utilized the Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), our in-house developed machine learning model, for predicting MHC class I presentation and identifying potentially immunogenic patient-specific neoantigens.